Cargando…

Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers

BACKGROUND AND OBJECTIVE: Gestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplem...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ya-Jie, Wang, Wen-Juan, Zhang, Qiu-Yi, Yang, Meng-Nan, Zhang, Lin, He, Hua, Dong, Yu, Ouyang, Fengxiu, Gao, Ying, Zhang, Jun, Zheng, Tao, Luo, Zhong-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069675/
https://www.ncbi.nlm.nih.gov/pubmed/37020805
http://dx.doi.org/10.3389/fnut.2023.1089131
_version_ 1785018894702870528
author Xu, Ya-Jie
Wang, Wen-Juan
Zhang, Qiu-Yi
Yang, Meng-Nan
Zhang, Lin
He, Hua
Dong, Yu
Ouyang, Fengxiu
Gao, Ying
Zhang, Jun
Zheng, Tao
Luo, Zhong-Cheng
author_facet Xu, Ya-Jie
Wang, Wen-Juan
Zhang, Qiu-Yi
Yang, Meng-Nan
Zhang, Lin
He, Hua
Dong, Yu
Ouyang, Fengxiu
Gao, Ying
Zhang, Jun
Zheng, Tao
Luo, Zhong-Cheng
author_sort Xu, Ya-Jie
collection PubMed
description BACKGROUND AND OBJECTIVE: Gestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin. METHODS: In a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24–28  weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes included high-molecular-weight (HMW) adiponectin and insulin-like growth factor-1 (IGF-1) concentrations in cord blood, maternal glycemic control post-intervention and birth weight (z score). In parallel, 38 euglycemic pregnant women were recruited for comparisons of cord blood biomarkers. RESULTS: There were no significant differences in cord serum leptin, total and HMW adiponectin and IGF-1 concentrations between DHA supplementation and control groups (all p > 0.05). Maternal fasting and 2-h postprandial blood glucose levels at 12–16 weeks post-intervention were similar between the two groups. The newborns in the DHA group had higher birth weight z scores (p = 0.02). Cord blood total and HMW adiponectin concentrations were significantly lower in GDM vs. euglycemic pregnancies. CONCLUSION: Docosahexaenoic acid supplementation at 500  mg/day in GDM women did not affect neonatal metabolic biomarkers including leptin, adiponectin and IGF-1. The results are reassuring in light of the absence of influence on neonatal adipokines (leptin and adiponectin), and potential benefits to fetal growth and development. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT03569501.
format Online
Article
Text
id pubmed-10069675
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100696752023-04-04 Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers Xu, Ya-Jie Wang, Wen-Juan Zhang, Qiu-Yi Yang, Meng-Nan Zhang, Lin He, Hua Dong, Yu Ouyang, Fengxiu Gao, Ying Zhang, Jun Zheng, Tao Luo, Zhong-Cheng Front Nutr Nutrition BACKGROUND AND OBJECTIVE: Gestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin. METHODS: In a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24–28  weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes included high-molecular-weight (HMW) adiponectin and insulin-like growth factor-1 (IGF-1) concentrations in cord blood, maternal glycemic control post-intervention and birth weight (z score). In parallel, 38 euglycemic pregnant women were recruited for comparisons of cord blood biomarkers. RESULTS: There were no significant differences in cord serum leptin, total and HMW adiponectin and IGF-1 concentrations between DHA supplementation and control groups (all p > 0.05). Maternal fasting and 2-h postprandial blood glucose levels at 12–16 weeks post-intervention were similar between the two groups. The newborns in the DHA group had higher birth weight z scores (p = 0.02). Cord blood total and HMW adiponectin concentrations were significantly lower in GDM vs. euglycemic pregnancies. CONCLUSION: Docosahexaenoic acid supplementation at 500  mg/day in GDM women did not affect neonatal metabolic biomarkers including leptin, adiponectin and IGF-1. The results are reassuring in light of the absence of influence on neonatal adipokines (leptin and adiponectin), and potential benefits to fetal growth and development. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT03569501. Frontiers Media S.A. 2023-03-20 /pmc/articles/PMC10069675/ /pubmed/37020805 http://dx.doi.org/10.3389/fnut.2023.1089131 Text en Copyright © 2023 Xu, Wang, Zhang, Yang, Zhang, He, Dong, Ouyang, Gao, Zhang, Zheng and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Xu, Ya-Jie
Wang, Wen-Juan
Zhang, Qiu-Yi
Yang, Meng-Nan
Zhang, Lin
He, Hua
Dong, Yu
Ouyang, Fengxiu
Gao, Ying
Zhang, Jun
Zheng, Tao
Luo, Zhong-Cheng
Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
title Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
title_full Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
title_fullStr Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
title_full_unstemmed Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
title_short Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
title_sort docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069675/
https://www.ncbi.nlm.nih.gov/pubmed/37020805
http://dx.doi.org/10.3389/fnut.2023.1089131
work_keys_str_mv AT xuyajie docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT wangwenjuan docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT zhangqiuyi docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT yangmengnan docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT zhanglin docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT hehua docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT dongyu docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT ouyangfengxiu docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT gaoying docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT zhangjun docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT zhengtao docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers
AT luozhongcheng docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers